



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
11.01.2023 Bulletin 2023/02

(45) Date of publication and mention
of the grant of the patent:
11.11.2015 Bulletin 2015/46

(21) Application number: **10184682.2**

(22) Date of filing: **26.09.2003**

(51) International Patent Classification (IPC):
C07K 16/00 ^(2006.01) **C07K 16/30** ^(2006.01)
C07K 16/28 ^(2006.01) **C07K 16/24** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07K 16/00; A61P 25/00; A61P 29/00;
A61P 31/00; A61P 35/00; A61P 37/00;
C07K 16/2893; C07K 16/2896; C07K 16/32;
A61K 2039/505; C07K 2317/34; C07K 2317/72;
C07K 2317/732; C07K 2317/734; C07K 2317/94

(54) **Optimized fc variants and methods for their generation**

OPTIMIERTE FC VARIANTEN UND METHODEN ZU IHRER HERSTELLUNG

Variantes FC optimisées et leurs procédés de génération

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: **27.09.2002 US 414433 P**
23.01.2003 US 442301 P
02.05.2003 US 467606 P
12.06.2003 US 477839 P

(43) Date of publication of application:
20.07.2011 Bulletin 2011/29

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
08020666.7 / 2 042 517
03773056.1 / 1 553 975

(73) Proprietor: **Xencor, Inc.**
Monrovia, CA 91016 (US)

(72) Inventors:
• **Lazar, Gregory Alan**
Glendale, CA 91202 (US)
• **Chirino, Arthur J.**
Camarillo, CA 91106 (US)
• **Dang, Wei**
Pasadena, CA 91101 (US)

- **Desjarlais, John Rudolph**
Pasadena, CA 91104 (US)
- **Doberstein, Stephen Kohn**
Pasadena, CA 91106 (US)
- **Hayes, Robert J.**
Paoli, PA 19301 (US)
- **Karki, Sher Busudur**
Pomona, CA 91767 (US)
- **Vafa, Omid**
Phoenixville, PA 19460 (US)

(74) Representative: **HGF**
HGF Limited
Saviour House
9 St. Saviourgate
York YO1 8NQ (GB)

(56) References cited:
WO-A2-00/42072

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII and FcRn and design of IgG1 variants with improved binding to the Fc gamma R", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 9, 2 March 2001 (2001-03-02) , pages 6591-6604, XP2495886, ISSN: 0021-9258
- JEFFERIS ROY ET AL: "Interaction sites on human IgG-Fc for FcgammaR: Current models", IMMUNOLOGY LETTERS, vol. 82, no. 1-2, 3 June 2002 (2002-06-03) , pages 57-65, XP002337953, ISSN: 0165-2478
- CANFIELD S M ET AL: "THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 173, no. 6, 1 June 1991 (1991-06-01), pages 1483-1491, XP001181027, ISSN: 0022-1007, DOI: DOI:10.1084/JEM.173.6.1483
- SONDERMANN P ET AL: "The 3.2-ANG crystal structure of the human IgG1 Fc fragment-FcgammaRIII complex", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 406, no. 6793, 20 July 2000 (2000-07-20), pages 267-273, XP002343993, ISSN: 0028-0836, DOI: DOI:10.1038/35018508
- IDUSOGIE ESOHE E ET AL: "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 164, 1 January 2000 (2000-01-01), pages 4178-4184, XP002965858, ISSN: 0022-1767